On October 29, Stryker cut its 2026 organic sales growth outlook to 6.5%–7.0%, down from a prior range topping out at 9.3% . Hip sales fell 1% in the quarter . Management named three causes — a market slowdown in joint replacement driven by higher deductibles and pre-authorization denials, plus its own lingering cyberattack disruption and a July SAP rollout in orthopedics — and the shares dropped 6.4% the next session . Six weeks earlier, the company that spent most of the past decade as medtech's designated non-grower had gone the other way: Medtronic raised its fiscal 2027 organic revenue guidance to 7.25%–7.75% after a quarter that grew 13.7% organic .
Medtronic today is three portfolios and a dividend. Fiscal 2026, which closed in April, produced $36.4 billion of revenue — Cardiovascular $14.0 billion, Neuroscience $10.3 billion, Medical Surgical $8.8 billion, plus a $3.1 billion diabetes business that has since been handed to shareholders outright. The operating turn behind that guidance raise is genuine and the next two quarters should look fine. The harder question, and the one this argument turns on, is what Medtronic now earns on the capital that the separation and a decade of cash generation have put in its hands. On that, the evidence is much weaker than the growth story suggests, and the share price at $96.54 — up 32% from a $73.31 low in early June — already reflects the good half.
The de-rating was a diabetes charge and a valve data set, not a demand problem
Three events in five months took the stock apart. On February 5, a California jury handed Applied Medical Resources a $382 million antitrust verdict over Medtronic's advanced bipolar contracting with group purchasing organizations — an award the court must automatically treble . On March 6, MiniMed, the diabetes unit, broke its IPO: marketed at $25 to $28, priced at $20, and closed its first session at $18.49 . On March 24, Medtronic cut fiscal 2026 non-GAAP EPS guidance to $5.50–$5.54 from $5.62–$5.66, on MiniMed arithmetic alone — a $157 million Blackstone royalty charge triggered by an unexpectedly early FDA clearance of...